Clinical trial
A Study to Investigate the Efficacy and Safety of Trastuzumab Deruxtecan as the…
NCT05048797 · AstraZeneca, Industry · Active, not recruiting
Key facts
| NCT number | NCT05048797 |
|---|---|
| Title | A Study to Investigate the Efficacy and Safety of Trastuzumab Deruxtecan as the First Treatment Option for Unresectable, Locally Advanced/Metastatic Non-Small Cell Lung Cancer With HER2 Mutations |
| Official title | An Open-label, Randomized, Multicenter, Phase 3 Study to Assess the Efficacy and Safety of Trastuzumab Deruxtecan as First-line Treatment of Unresectable, Locally Advanced, or Metastatic NSCLC Harboring HER2 Exon 19 or 20 Mutations (DESTINY-Lung04) |
| Lead sponsor | AstraZeneca, Industry |
| Collaborators | Daiichi Sankyo Industry |
| Status | Active, not recruiting |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Locally Advanced or Metastatic Non-Small Cell Lung Cancer |
| Intervention type | Drug |
| Interventions | Trastuzumab Deruxtecan, Cisplatin, Carboplatin, Pembrolizumab, Pemetrexed |
| Enrollment | 454 |
| Start date | Oct 28, 2021 |
| Primary completion | Mar 30, 2026 |
| Completion | Jul 30, 2027 |
| First posted | Sep 17, 2021 |
| Last update posted | Dec 23, 2025 |
| Countries | Austria, Belgium, Brazil, Canada, China, Denmark, France, Germany, Hong Kong, India, Italy, Japan and 8 more |
At a glance
- 100–999 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: